Atherogenics (AGIX) Inactive 10-Q2006 Q1 Quarterly report

Filed: 8 May 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: Add, administered, assigned, Assuming, AstraZeneca, automated, balance, bearing, billed, calculated, carryforward, charge, comprised, concomitant, conformity, consideration, demanding, detect, eligible, exclusive, face, forfeiture, free, global, greater, incentive, induce, Induced, installation, Judge, labeling, law, licensee, milestone, national, NDA, nonrefundable, oversee, owed, packaging, percent, pharmacological, power, premium, produce, professional, Prograf, progressively, provision, receipt, regimen, remain, restricted, SAB, service, sheet, software, specific, specifically, system, tax, tradable, transaction, Treasury, twenty, ultimately, unamortized, underlying, understanding, unsuccessful, upfront, vest, volatility, worldwide, yield

Removed: accelerate, acceptance, adjust, affecting, amendment, analyze, auction, Bank, bring, clinically, comparable, compound, dated, decrease, dependent, disclosed, discontinued, eliminate, endothelial, enhance, enroll, equal, equivalent, escalating, establish, excluding, expand, expression, facility, finance, Fujisawa, function, functional, gene, increased, initial, inside, intended, lining, liquidated, maturity, maximum, mild, minimum, modify, month, negative, offering, originally, pace, planned, pledge, present, properly, proposed, reached, reclassification, redemption, reliably, scientific, Silicon, single, studied, subsequent, targeted, terminated, therapeutic, unpaid, Valley, variety

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AGIX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AtheroGenics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Russell M. Medford, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/RUSSELL M. MEDFORD

Russell M. Medford

President and Chief Executive Officer

Date: May 8, 2006

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AtheroGenics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark P. Colonnese, Senior Vice President of Finance and Administration and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/MARK P. COLONNESE

Mark P. Colonnese

Senior Vice President of Finance and Administration

and Chief Financial Officer

Date: May 8, 2006

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.